Press Release

Versartis Announces Confirmatory 18-Month Data From Ongoing Extension Study of Growth-Hormone-XTEN (VRS-317, Somavaratan) in Children

(Amunix out-licensed VRS-317, a fusion protein consisting of rhGH and XTEN, to Versartis in 2008).

Read about it here: Versartis Study Announcement